Provided herein are pharmaceutical compositions and methods for treatment or prevention of synucleinopathies with small-molecule inhibitors of pathogenic α-synuclein activity having the Formula (I). Also, provide are methods for identifying novel compounds for modulating α-synuclein activity.

Provided herein are pharmaceutical compositions and methods for treatment or prevention of synucleinopathies with small-molecule inhibitors of pathogenic α-synuclein activity having the Formula (I). Also, provide are methods for identifying novel compounds for modulating α-synuclein activity.

The present invention provides compounds, compositions thereof, and methods of using the same.

The present invention provides compounds, compositions thereof, and methods of using the same.

This invention provides 1-pyridyl pyrazole amide compounds represented by Formula (I) and preparation and uses thereof, wherein each substituent is defined in the disclosure. The compounds of Formula (I) of this invention possess excellent insecticidal activities, especially very strong activities against pests such as aphids, armyworms and diamondback moths, etc., and can be used to control various pests. This invention also provides synthetic intermediates represented by Formula (II) for preparing compounds of Formula (I) wherein each substituent is defined in the specification.

##STR00001##

Disclosed are three-component crystals comprising compounds of Formula II, compounds of Formula III and an amine base in an equimolar ratio (1:1:1). Also disclosed are methods for preparing the three-component crystals comprising compounds of Formula II, compounds of Formula III and an amine base in an equimolar ratio (1:1:1). Further disclosed are methods for the preparation of chlorantraniliprole using the three-component crystals of the disclosure.

Disclosed are three-component crystals comprising compounds of Formula II, compounds of Formula III and an amine base in an equimolar ratio (1:1:1). Also disclosed are methods for preparing the three-component crystals comprising compounds of Formula II, compounds of Formula III and an amine base in an equimolar ratio (1:1:1). Further disclosed are methods for the preparation of chlorantraniliprole using the three-component crystals of the disclosure.

The present disclosure relates to compounds that are capable of inhibiting the ENPP1 gene and treating a variety of cardiac conditions. The disclosure further relates to methods of treating or preventing cardiac conditions, such as myocardial infarction and heart failure.

The present invention relates to a process for the preparation of Apalutamide of formula (A) Apalutamide is a latest-generation androgen receptor inhibitor, used to treat non-metastatic castration-resistant prostate cancer. ##STR00001##

The present invention relates to a process for the preparation of Apalutamide of formula (A) Apalutamide is a latest-generation androgen receptor inhibitor, used to treat non-metastatic castration-resistant prostate cancer. ##STR00001##